Le Lézard
Classified in: Health
Subject: PDT

Tekscan Introduces T-Scan Novus Core, a Cost-Effective, Entry-Level Digital Occlusal Analysis System for General Dental Practices


BOSTON, Jan. 25, 2021 /PRNewswire/ -- Tekscan, Inc. is pleased to introduce T-Scantm Novustm Coretm, a new digital occlusal analysis system developed for general dentists who are beginning to incorporate digital technologies into their practice.

T-Scan Novus Core is the essential entry-level system that provides dentists with essential bite force and timing for easy analysis. Using contact data points in conjunction with analog occlusion methods ? like articulating paper ? helps dentists pinpoint exact areas in the patient's mouth that may require an adjustment

T-Scan Novus Core consists of a patented sensor, ergonomic handpiece, and proprietary analysis software that captures and reveals the relative force and timing of a patient's bite. This data helps the dentist pinpoint high forces on specific teeth to adjust and improve the patient's bite stability.

"Digital dental technologies have become a must for dental practices in recent years. We know that incorporating new technologies into a practice can be overwhelming. That's why we developed T-Scan Novus Core as a lower-cost offering with basic analysis essentials, allowing dentists to explore and understand how digital occlusal analysis data can positively impact their workflow and treatment accuracy." says Jennifer Cullen, Manager of Dental Sales and Business Development for Tekscan.

Introduced over 35 years ago, T-Scan is the dental industry's first and only research-validated digital occlusal analysis system used by dentists worldwide to obtain more occlusal information and improve treatment outcomes. T-Scan Novus Core is the second product under the T-Scan Novus family of products. T-Scan Novus with v10 software, a more comprehensive digital occlusal analysis system, includes many additional features and technology-integration capabilities to help dentists expand and enhance their digital dentistry portfolio. 

For more information, visit www.tekscan.com/t-scan-novus-core, or contact Diana Hamblin at 617.464.4500 ext. 344 and [email protected].

About Tekscan

Since its founding in 1987 and located in the Innovation District of Boston, Tekscan has been at the forefront in the research and development of ultra-thin force and pressure sensing technology for use across a wide range of applications. With a unique patent portfolio and proprietary technology, Tekscan maintains its world-leading position in the area of tactile force and pressure sensing by providing customers with actionable information they need to optimize product design, and improve clinical and research outcomes.  For more information on Tekscan, visit www.tekscan.com.

For more information, contact:

Diana Hamblin, Marketing Program Manager

Tel: 617.464.4500 ext. 344, Email: [email protected]

SOURCE Tekscan


These press releases may also interest you

at 09:15
Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company") today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have both recommended that Taro shareholders...

at 09:13
Advanced Laparoscopic Surgeons of Morris announces partnership with New York Bariatric Group (NYBG), the nation's leading private bariatric service provider offering bariatric surgical procedures and physician supervised weight loss with GLP-1...

at 09:12
Introducing the bt-sculpt®, a revolutionary facial toning unit created by Bio-Therapeutic, a family-owned legacy brand widely recognized as the leader in microcurrent technology. Designed to deliver the ultimate skin fitness experience by providing...

at 09:10
Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today the final results of their pilot research study with The Feinstein Institutes for Medical...

at 09:09
For decades, the inhaler has been the go-to treatment for asthma, but innovative options like biologics are changing how providers tailor care....

at 09:09
Implantica AG (publ) invites investors to a presentation of the first quarter 2024 at 15:00 CEST on May 15. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day. The presentation will be in English via an...



News published on and distributed by: